Novel treatment paradigms for autoimmune and chronic inflammatory skin conditions
MC2 therapeutics is converting skin biology into novel treatment paradigms for autoimmune and inflammatory skin conditions. Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fuelled by an entrepreneurial and creative mindset we aim to bring forward breakthrough discoveries and innovative technologies. Our drug candidates are powered by our proprietary formulation and drug delivery system PAD Technology™.
Breakthrough discoveries of novel treatment paradigms are just the beginning. We also apply our expertise in formulation and clinical development to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.
There is a major unmet need to significantly upgrade the patient treatment experience with topical therapies that – in one single product – can provide the three essentials:
(i) EFFICACY: Fast onset and high efficacy;
(ii) TOLERABILITY: Favourable tolerability and safety profile;
(iii) ADHERENCE: Formulations that motivates high adherence in daily routines.
Topical therapies may be difficult to develop for reasons of poor stability or lack of solubility of the active ingredients or difficulties in delivering active ingredients into the target tissue. This often results in compromised formulations that do not release the full potential of the active ingredients or use of allergenic or greasy ingredients that people do not like to use in their daily routines, due to suboptimal efficacy, greasiness (stain clothes and bedding), tolerability issues or other unwanted side effects.